Dornase alfa (Pulmozyme)

Current Opinion in Pulmonary Medicine

Volumn 18, Issue 6, 2012, Pages 609-614

  Wagener, Jeffrey S ^a   Kupfer, Oren ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

cystic fibrosis; dornase alfa; lung disease; Pulmozyme; rhDNase

Indexed keywords

CORTICOSTEROID; DORNASE ALFA; GELATINASE B; IBUPROFEN; INTERLEUKIN 8; NEUTROPHIL COLLAGENASE; PLACEBO; TISSUE PLASMINOGEN ACTIVATOR;

ARTIFICIAL VENTILATION; ASTHMA; ATELECTASIS; BRONCHOSCOPY; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG TOLERABILITY; EMPYEMA; FORCED EXPIRATORY VOLUME; HUMAN; IN VITRO STUDY; LONG TERM CARE; LUNG CLEARANCE; LUNG FUNCTION; LUNG LAVAGE; NEUTROPHIL; OUTPATIENT CARE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PLEURA EFFUSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFLAMMATION; REVIEW; SINUSITIS; SURVIVAL; TREATMENT DURATION;

CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; HUMANS; RECOMBINANT PROTEINS;

EID: 84867069529     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328358d51f     Document Type: Review

References (29)

1. Lazarus RA, Wagener JS. Recombinant human deoxyribonuclease 1. In: Crommelin DJA, Sindelar RD, Neibohm B, editors. Pharmaceutical biotechnology: fundamentals and applications. 3rd ed. New York: Informa Healthcare; 2008. pp. 387-398.
2. Jones AP, Wallis C. Dornase alfa for cystic fibrosis. Cochrane Database Syst Rev 2010:CD001127.
3. Konstan MW, Van Devanter DR, Rasouliyan L, et al. Trends in the use of routine therapies in cystic fibrosis: 1995-2005. Pediatr Pulmonol 2010; 45:1167-1172.
4. Glauser TA, Nevins PH, Williamson JC, et al. Adherence to the 2007 cystic fibrosis pulmonary guidelines: a national survey of CF care centers. Pediatr Pulmonol 2012; 47:434-440.
5. Tiddens HA. Editorial for effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012; 11:77.
6. Amin R, Subbarao P, Lou W, et al. The effect of dornase alfa on ventilation inhomogeneity in patients with cystic fibrosis. Eur Respir J 2011; 37:806-812.
7. Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011; 38:1071-1080.
8. Kaplan JB, LoVetri K, Cardona ST, et al. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo) 2012; 65:73-77.
9. Bonestroo HJ, Slieker MG, Arets HG. No positive effect of rhdnase on the pulmonary colonization in children with cystic fibrosis. Monaldi Arch Chest Dis 2010; 73:12-17.
10. Paul K, Rietschel E, Ballmann M, et al. Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis. Am J Respir Crit Care Med 2004; 169:719-725.
11. Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012; 11:78-83.
12. Eakin MN, Bilderback A, Boyle MP, et al. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros 2011; 10:258-264.
13. Scherer T, Geller DE, Owyang L, et al. A technical feasibility study of dornase alfa delivery with eFlow vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci 2010; 100:98-109.
14. Bakker EM, Volpi S, Salonini E, et al. Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation. Eur Respir J 2012; 38:1328-1335.
15. McCormack P, McNamara PS, Southern KW. A randomised controlled trial of breathing modes for adaptive aerosol delivery in children with cystic fibrosis. J Cyst Fibros 2011; 10:343-349.
16. Bishop JR, Erskine OJ, Middleton PG. Timing of dornase alpha inhalation does not affect the efficacy of an airway clearance regimen in adults with cystic fibrosis: a randomised crossover trial. J Physiother 2011; 57:223-229.
17. Dentice R, Elkins M. Timing of dornase alfa inhalation for cystic fibrosis. Cochrane Database Syst Rev 2011:CD007923.
18. Konstan MW, Wagener JS, Pasta DJ, et al. Clinical use of dornase alpha is associated with a slower rate of FEV1 decline in cystic fibrosis. Pediatr Pulmonol 2011; 46:545-553.
19. McPhail GL, Weiland J, Acton JD, et al. Improving evidence-based care in cystic fibrosis through quality improvement. Arch Pediatr Adolesc Med 2010; 164:957-960.
20. Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012; 47:44-52.
21. Briesacher BA, Quittner AL, Fouayzi H, et al. Nationwide trends in the medical care costs of privately insured patients with cystic fibrosis (CF), 2001-2007. Pediatr Pulmonol 2011; 46:770-776.
22. Dewitt EM, Grussemeyer CA, Friedman JY, et al. Resource use, costs, and utility estimates for patients with cystic fibrosis with mild impairment in lung function: analysis of data collected alongside a 48-week multicenter clinical trial. Value Health 2012; 15:277-283.
23. Rahman NM, Maskell NA, West A, et al. Intrapleural use of tissue plasminogen activator and DNase in pleural infection. N Engl J Med 2011; 365:518-526.
24. MacKinnon R, Wheeler KI, Sokol J. Endotracheal DNase for atelectasis in ventilated neonates. J Perinatol 2011; 31:799-801.
25. Fedakar A, Aydogdu C, Ugurlucan M, et al. Safety of recombinant human deoxyribonuclease as a rescue treatment for persistent atelectasis in newborns. Ann Saudi Med 2012; 32:131-136.
26. Dilmen U, Karagol BS, Oguz SS. Nebulized hypertonic saline and recombinant human DNase in the treatment of pulmonary atelectasis in newborns. Pediatr Int 2011; 53:328-331.
27. Altunhan H, Annagur A, Pekcan S, et al. Comparing the efficacy of nebulizer recombinant human DNase and hypertonic saline as monotherapy and combined treatment in the treatment of persistent atelectasis in mechanically ventilated newborns. Pediatr Int 2012; 54:131-136.
28. Silverman RA, Foley F, Dalipi R, et al. The use of rhDNAse in severely ill, nonintubated adult asthmatics refractory to bronchodilators: a pilot study. Respir Med 2012; 106:1096-1102.
29. Mainz JG, Schiller I, Ritschel C, et al. Sinonasal inhalation of dornase alfa in CF: a double-blind placebo-controlled cross-over pilot trial. Auris Nasus Larynx 2011; 38:220-227.